TransMedics Group, Inc.
TMDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $143,823 | $157,370 | $143,537 | $121,624 |
| % Growth | -8.6% | 9.6% | 18% | – |
| Cost of Goods Sold | $59,248 | $60,781 | $55,309 | $49,611 |
| Gross Profit | $84,575 | $96,589 | $88,228 | $72,013 |
| % Margin | 58.8% | 61.4% | 61.5% | 59.2% |
| R&D Expenses | $15,260 | $15,934 | $17,160 | $16,464 |
| G&A Expenses | $0 | $44,088 | $43,625 | $46,905 |
| SG&A Expenses | $46,015 | $44,088 | $43,625 | $46,905 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61,275 | $60,022 | $60,785 | $63,369 |
| Operating Income | $23,300 | $36,567 | $27,443 | $8,644 |
| % Margin | 16.2% | 23.2% | 19.1% | 7.1% |
| Other Income/Exp. Net | -$269 | -$385 | -$767 | -$1,655 |
| Pre-Tax Income | $23,031 | $36,182 | $26,676 | $6,989 |
| Tax Expense | -$1,288 | $1,275 | $994 | $132 |
| Net Income | $24,319 | $34,907 | $25,682 | $6,857 |
| % Margin | 16.9% | 22.2% | 17.9% | 5.6% |
| EPS | 0.71 | 1.03 | 0.76 | 0.2 |
| % Growth | -31.1% | 35.5% | 280% | – |
| EPS Diluted | 0.66 | 0.92 | 0.7 | 0.19 |
| Weighted Avg Shares Out | 34,112 | 33,913 | 33,722 | 33,592 |
| Weighted Avg Shares Out Dil | 40,748 | 40,559 | 39,914 | 35,211 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2,500 | $0 | $2,916 |
| Interest Expense | $3,491 | $3,476 | $3,461 | $3,571 |
| Depreciation & Amortization | $6,849 | $6,731 | $6,137 | $5,680 |
| EBITDA | $33,371 | $46,389 | $36,274 | $16,240 |
| % Margin | 23.2% | 29.5% | 25.3% | 13.4% |